JP2012529535A - キナーゼモジュレーターとして有用なニコチンアミド化合物 - Google Patents

キナーゼモジュレーターとして有用なニコチンアミド化合物 Download PDF

Info

Publication number
JP2012529535A
JP2012529535A JP2012515123A JP2012515123A JP2012529535A JP 2012529535 A JP2012529535 A JP 2012529535A JP 2012515123 A JP2012515123 A JP 2012515123A JP 2012515123 A JP2012515123 A JP 2012515123A JP 2012529535 A JP2012529535 A JP 2012529535A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
alkoxy
substituted
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012515123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529535A5 (enExample
Inventor
ジョージ・ブイ・デルッカ
キン・シ
チュンジアン・リュー
ジンウ・デュアン
アンドリュー・ジェイ・テッベン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2012529535A publication Critical patent/JP2012529535A/ja
Publication of JP2012529535A5 publication Critical patent/JP2012529535A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012515123A 2009-06-12 2010-06-10 キナーゼモジュレーターとして有用なニコチンアミド化合物 Pending JP2012529535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18641709P 2009-06-12 2009-06-12
US61/186,417 2009-06-12
PCT/US2010/038079 WO2010144647A1 (en) 2009-06-12 2010-06-10 Nicotinamide compounds useful as kinase modulators

Publications (2)

Publication Number Publication Date
JP2012529535A true JP2012529535A (ja) 2012-11-22
JP2012529535A5 JP2012529535A5 (enExample) 2013-06-27

Family

ID=42543320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515123A Pending JP2012529535A (ja) 2009-06-12 2010-06-10 キナーゼモジュレーターとして有用なニコチンアミド化合物

Country Status (6)

Country Link
US (1) US8586751B2 (enExample)
EP (1) EP2440204B1 (enExample)
JP (1) JP2012529535A (enExample)
CN (1) CN102458402B (enExample)
ES (1) ES2444777T3 (enExample)
WO (1) WO2010144647A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534056A (ja) * 2013-10-21 2016-11-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害剤としてのヘテロアリール化合物及びその使用
JP2016539152A (ja) * 2013-12-05 2016-12-15 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
JP2017501202A (ja) * 2014-01-03 2017-01-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のニコチンアミド化合物
JP2017507979A (ja) * 2014-03-17 2017-03-23 ファイザー・インク 代謝性および関連障害の処置において使用するためのジアシルグリセロールアシルトランスフェラーゼ２阻害剤
JP2020536093A (ja) * 2017-10-11 2020-12-10 デウン ファーマシューティカル カンパニー リミテッド 新規なフェニルピリジン誘導体およびこれを含む薬学組成物
JP2022508705A (ja) * 2018-10-15 2022-01-19 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
BR112012033770A2 (pt) 2010-06-30 2016-11-22 Fujifilm Corp novo derivado de nicotinamida ou sal do mesmo
WO2012061418A2 (en) * 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
PT2718270T (pt) * 2011-06-10 2022-07-29 Merck Patent Gmbh Composições e métodos para a produção de compostos de pirimidina e piridina com atividade inibidora de btk
US9782406B2 (en) 2011-10-25 2017-10-10 Peking University Shenzhen Graduate School Kinase inhibitor and method for treatment of related diseases
CN103073508B (zh) * 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
WO2013099041A1 (ja) * 2011-12-28 2013-07-04 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
JP6134376B2 (ja) * 2012-03-16 2017-05-24 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
BR112015007217A2 (pt) * 2012-10-19 2017-08-08 Hoffmann La Roche compostos e usos do composto
CN104903301B (zh) * 2012-11-08 2017-08-29 百时美施贵宝公司 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物
JP6215338B2 (ja) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
KR20150079963A (ko) 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
CN104109127B (zh) * 2013-04-19 2019-11-05 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
CA2902686C (en) 2013-04-25 2017-01-24 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
CN108715615B (zh) 2013-09-13 2020-11-27 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN104341388B (zh) * 2013-10-16 2017-03-22 北京诺诚健华医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
GB201319277D0 (en) * 2013-10-31 2013-12-18 Akthelia Pharmaceuticals A new class of inducers of antimicrobial compounds
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
UY36371A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
CN104672219A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途
CN104672218A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途
WO2016210036A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
US10294229B2 (en) 2015-06-24 2019-05-21 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
DK3500299T3 (da) 2016-08-19 2024-01-29 Beigene Switzerland Gmbh Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
MX390121B (es) 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CA3062602A1 (en) 2017-05-11 2018-11-15 Bristol-Myers Squibb Company Thienopyridines and benzothiophenes useful as irak4 inhibitors
CN110799543A (zh) 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
JP7406264B2 (ja) 2018-11-20 2023-12-27 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのシアノアリール－アニリン化合物
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
KR20220035447A (ko) 2019-07-18 2022-03-22 브리스톨-마이어스 스큅 컴퍼니 IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
ES2983263T3 (es) 2019-08-06 2024-10-22 Bristol Myers Squibb Co Compuestos heterocíclicos bicíclicos útiles como inhibidores de IRAK4
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
US12421230B2 (en) 2020-02-03 2025-09-23 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as IRAK4 inhibitors
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用
US20240360146A1 (en) * 2021-07-01 2024-10-31 Hangzhou Healzen Therapeutics Co., Ltd. Bruton's tyrosine kinase and mutant degrader, composition and application thereof
US12377106B2 (en) 2021-10-26 2025-08-05 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
MX2024008480A (es) * 2022-01-07 2024-07-15 Chugai Pharmaceutical Co Ltd Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2).
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001055378A (ja) * 1999-06-09 2001-02-27 Yamanouchi Pharmaceut Co Ltd 新規なヘテロ環カルボキサミド誘導体
JP2008013499A (ja) * 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132603C (enExample) 1964-08-29
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5104877A (en) 1991-02-25 1992-04-14 Abbott Laboratories Psoriasis treatment
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US5972975A (en) 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
ZA977427B (en) 1996-09-04 1998-03-02 Dainippon Pharmaceutical Co 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
EP1028950B1 (en) 1997-10-28 2003-05-02 Warner-Lambert Company LLC 7-substituted quinazolin-2,4-diones useful as antibacterial agents
ES2308821T3 (es) 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.
IL144717A0 (en) 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
DE60017898T2 (de) * 1999-06-09 2006-01-12 Yamanouchi Pharmaceutical Co., Ltd. Neuartige heterocyclische carboxamidderivate
KR100532546B1 (ko) 1999-09-16 2005-12-01 다나베 세이야꾸 가부시키가이샤 방향족 질소 함유 6-원 고리 화합물
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2002213466A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
JP4178816B2 (ja) 2001-03-15 2008-11-12 田辺三菱製薬株式会社 医薬組成物
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003272324A1 (en) 2002-09-10 2004-04-30 Scios Inc. INHIBITORS OF TFGBeta
US20040116479A1 (en) 2002-10-04 2004-06-17 Fortuna Haviv Method of inhibiting angiogenesis
ES2285409T3 (es) 2003-01-16 2007-11-16 Sb Pharmco Puerto Rico Inc Derivados pirrol(2,3-b)piridina sustituidos con heteroarilo como antagonistas del receptor de crf.
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1678146A1 (en) 2003-10-23 2006-07-12 Pharmacia Corporation Pyrimidine compounds for the treatment of inflammation
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
CN101676285A (zh) 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
US20050288502A1 (en) 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
AU2005289426A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
BRPI0517619A (pt) 2004-11-10 2008-10-14 Cgi Pharmaceuticals Inc entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
WO2006088919A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1863766B1 (en) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
US7468382B2 (en) 2005-03-28 2008-12-23 Boehringer Ingelheim International Gmbh Pyridine derivatives useful as inhibitors of PKC-theta
EP1879564B1 (en) 2005-04-07 2009-12-23 Astrum Therapeutics Pty, Ltd. Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
AU2006247482A1 (en) 2005-05-13 2006-11-23 Lexicon Pharmaceuticals, Inc. Multicyclic compounds and methods of their use
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
US20090203744A1 (en) 2005-07-29 2009-08-13 Pande Y Surendrakumar Satyanarayan Novel pyridine derivatives
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20090131420A1 (en) 2005-10-07 2009-05-21 Pandey Surendrakumar S Novel Heterocyclic Analogs of Biphenyl Ethers
EP2388258A1 (de) 2005-10-19 2011-11-23 Grünenthal GmbH Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
JP5169220B2 (ja) 2005-11-30 2013-03-27 アステラス製薬株式会社 ２−アミノベンズアミド誘導体
EP1984353B1 (en) 2006-01-23 2015-12-30 Amgen, Inc Aurora kinase modulators and method of use
US20070208164A1 (en) 2006-02-27 2007-09-06 Wyeth Methods of synthesizing radiolabeled 3-cyano[14C]quinolines
CN101484449A (zh) 2006-04-28 2009-07-15 艾维克有限公司 整合酶抑制剂-3
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20090318389A1 (en) 2006-08-04 2009-12-24 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1 phosphate receptor
US20080076800A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
JPWO2008044713A1 (ja) 2006-10-10 2010-02-18 日本農薬株式会社 置換ピリジンカルボン酸アニリド誘導体又はその塩類、及び農園芸用薬剤並びにその使用方法
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US7915287B2 (en) 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
AU2008314632B2 (en) 2007-10-19 2015-05-28 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001055378A (ja) * 1999-06-09 2001-02-27 Yamanouchi Pharmaceut Co Ltd 新規なヘテロ環カルボキサミド誘導体
JP2008013499A (ja) * 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5012014077; ＮＡＧＡＳＨＩＭＡ: 'ＳＹＮＴＨＥＳＩＳ　ＡＮＤ　ＥＶＡＬＵＡＴＩＯＮ　ＯＦ　２-｛［２-（４-ＨＹＤＲＯＸＹＰＨＥＮＹＬ）-ＥＴＨＹＬ］ＡＭＩＮＯ｝ＰＹＲＩＭＩＤＩＮＥ-以下備考' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖ１５　Ｎ２, 20061212, Ｐ１０４４-１０５５, ＰＥＲＧＡＭＯＮ *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534056A (ja) * 2013-10-21 2016-11-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害剤としてのヘテロアリール化合物及びその使用
JP2016539152A (ja) * 2013-12-05 2016-12-15 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
JP2020121988A (ja) * 2013-12-05 2020-08-13 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
JP2017501202A (ja) * 2014-01-03 2017-01-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のニコチンアミド化合物
JP2017507979A (ja) * 2014-03-17 2017-03-23 ファイザー・インク 代謝性および関連障害の処置において使用するためのジアシルグリセロールアシルトランスフェラーゼ２阻害剤
JP2020536093A (ja) * 2017-10-11 2020-12-10 デウン ファーマシューティカル カンパニー リミテッド 新規なフェニルピリジン誘導体およびこれを含む薬学組成物
US11149019B2 (en) 2017-10-11 2021-10-19 Daewoong Pharmaceutical Co., Ltd. Phenylpyridine derivative and pharmaceutical composition comprising the same
JP2022508705A (ja) * 2018-10-15 2022-01-19 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
JP2025036439A (ja) * 2018-10-15 2025-03-14 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
JP7741282B2 (ja) 2018-10-15 2025-09-17 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物

Also Published As

Publication number Publication date
ES2444777T3 (es) 2014-02-26
US20120082702A1 (en) 2012-04-05
CN102458402B (zh) 2013-10-02
US8586751B2 (en) 2013-11-19
EP2440204B1 (en) 2013-12-18
CN102458402A (zh) 2012-05-16
EP2440204A1 (en) 2012-04-18
WO2010144647A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
JP2012529535A (ja) キナーゼモジュレーターとして有用なニコチンアミド化合物
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
JP7490107B2 (ja) スルホンピリジンアルキルアミド置換ヘテロアリール化合物
KR102549952B1 (ko) 키나제 억제제로서의 아미노트리아졸로피리딘
US10544133B2 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
JP6215338B2 (ja) キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
JP7485609B2 (ja) ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
CN107074867B (zh) 作为jak抑制剂的氨基嘧啶基化合物
JP2010522241A (ja) 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
JP2011529073A (ja) キナーゼ調節因子として有用な縮合ヘテロ環化合物
US20110092505A1 (en) Organic compounds
WO2016147659A1 (en) Bicyclic imidazolo derivative
KR20040062557A (ko) 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체
MXPA04011470A (es) Compuestos heterociclicos sustituidos y metodos de uso.
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
EP3523292A1 (en) Heteroaryl compounds and their use as mer inhibitors
JP2010504330A (ja) アルツハイマー病治療のためのピペリジンおよびピロリジンベータ−セクレターゼ阻害剤
MXPA06001002A (es) Piridonas y pirimidinonas sustituidas con propiedades antiinflamatorias.
HK1241857B (zh) 作为jak抑制剂的氨基嘧啶基化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150310